Intervention Review

You have free access to this content

Intermittent preventive treatment for malaria in children living in areas with seasonal transmission

  1. Martin M Meremikwu1,*,
  2. Sarah Donegan2,
  3. David Sinclair2,
  4. Ekpereonne Esu3,
  5. Chioma Oringanje4

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 15 FEB 2012

Assessed as up-to-date: 16 JUN 2011

DOI: 10.1002/14651858.CD003756.pub4


How to Cite

Meremikwu MM, Donegan S, Sinclair D, Esu E, Oringanje C. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD003756. DOI: 10.1002/14651858.CD003756.pub4.

Author Information

  1. 1

    University of Calabar Teaching Hospital, Department of Paediatrics, Calabar, Cross River State, Nigeria

  2. 2

    Liverpool School of Tropical Medicine, International Health Group, Liverpool, Merseyside, UK

  3. 3

    University of Calabar Teaching Hospital, Effective Health Care Research Programme - Nigeria, Calabar, Nigeria

  4. 4

    University of Calabar Teaching Hospital, Institute of Tropical Disease Research and Prevention, Calabar, Cross River, Nigeria

*Martin M Meremikwu, Department of Paediatrics, University of Calabar Teaching Hospital, PMB 1115, Calabar, Cross River State, Nigeria. mmeremiku@yahoo.co.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 15 FEB 2012

SEARCH

[Figure 1]
Figure 1. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Analysis 1.1]
Analysis 1.1. Comparison 1 IPTc versus placebo or no IPTc, Outcome 1 Clinical malaria.
[Analysis 1.2]
Analysis 1.2. Comparison 1 IPTc versus placebo or no IPTc, Outcome 2 Severe malaria.
[Analysis 1.3]
Analysis 1.3. Comparison 1 IPTc versus placebo or no IPTc, Outcome 3 Parasitaemia.
[Analysis 1.4]
Analysis 1.4. Comparison 1 IPTc versus placebo or no IPTc, Outcome 4 Death from any cause.
[Analysis 1.5]
Analysis 1.5. Comparison 1 IPTc versus placebo or no IPTc, Outcome 5 Hospital admission for any reason.
[Analysis 1.6]
Analysis 1.6. Comparison 1 IPTc versus placebo or no IPTc, Outcome 6 Severe anaemia.
[Analysis 1.7]
Analysis 1.7. Comparison 1 IPTc versus placebo or no IPTc, Outcome 7 Moderately severe anaemia.
[Analysis 1.8]
Analysis 1.8. Comparison 1 IPTc versus placebo or no IPTc, Outcome 8 Any anaemia.
[Analysis 1.9]
Analysis 1.9. Comparison 1 IPTc versus placebo or no IPTc, Outcome 9 Haemoglobin.
[Analysis 2.1]
Analysis 2.1. Comparison 2 IPTc versus placebo or no IPTc (subgroup analysis: additional interventions), Outcome 1 Clinical malaria.
[Analysis 2.2]
Analysis 2.2. Comparison 2 IPTc versus placebo or no IPTc (subgroup analysis: additional interventions), Outcome 2 Parasitaemia.
[Analysis 2.3]
Analysis 2.3. Comparison 2 IPTc versus placebo or no IPTc (subgroup analysis: additional interventions), Outcome 3 Moderately severe anaemia.
[Analysis 2.4]
Analysis 2.4. Comparison 2 IPTc versus placebo or no IPTc (subgroup analysis: additional interventions), Outcome 4 Any anaemia.
[Analysis 3.1]
Analysis 3.1. Comparison 3 IPTc versus placebo or no IPTc (subgroup analysis: type of antimalarial drug), Outcome 1 Clinical malaria.
[Analysis 3.2]
Analysis 3.2. Comparison 3 IPTc versus placebo or no IPTc (subgroup analysis: type of antimalarial drug), Outcome 2 Parasitaemia.
[Analysis 3.3]
Analysis 3.3. Comparison 3 IPTc versus placebo or no IPTc (subgroup analysis: type of antimalarial drug), Outcome 3 Moderately severe anaemia.
[Analysis 4.1]
Analysis 4.1. Comparison 4 IPTc (SP +AQ) versus placebo or no IPTc, Outcome 1 Non-serious adverse events (during intervention).
[Analysis 5.1]
Analysis 5.1. Comparison 5 IPTc (AS+SP) versus placebo or no IPTc, Outcome 1 Non-serious adverse events (during intervention).